Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions-Reference-Cited by-同舟云学术

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions

Published:2018-10-05 Issue:24 Volume:124 Page:4601-4609
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Steensma David P.¹,Brunner Andrew M.²,DeZern Amy E.³,Garcia‐Manero Guillermo⁴,Komrokji Rami S.⁵,Odenike Olatoyosi S.⁶,Roboz Gail J.⁷,Savona Michael R.⁸,Stone Richard M.¹,Sekeres Mikkael A.⁹

Affiliation:

1. Division of Hematological Malignancies, Department of Medical Oncology, Dana‐Farber Cancer Institute Boston Massachusetts

2. Division of Hematology and Medical Oncology, Department of Medicine Massachusetts General Hospital Boston Massachusetts

3. Division of Hematological Malignancies Sidney Kimmel Cancer Center, Johns Hopkins University Baltimore Maryland

4. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

5. Moffitt Cancer Center, Malignant Hematology Department Tampa Florida

6. Division of Hematology and Medical Oncology, Department of Medicine University of Chicago Chicago Illinois

7. Division of Hematology & Oncology Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine New York New York

8. Division of Hematology & Oncology Vanderbilt‐Ingram Cancer Center Nashville Tennessee

9. Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland Ohio

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31769

Reference77 articles.

1. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?

2. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement

3. Biotechnology Innovation Organization. Clinical development success rates 2006–2015.2018;https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO %20Biomedtracker %20Amplion%202016.pdf. Accessed April 9.

4. Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease;Journal of Hematology & Oncology;2022-08-31

2. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?;Blood Advances;2022-05-05

3. Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center;Leukemia Research;2021-09

4. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub;Blood Advances;2020-12-05

5. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes;Cancer;2020-08-07